Peking University Cancer Hospital & Institute
Peking University Cancer Hospital & Institute
Beijing, Beijing Municipality, China5 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, fallopian tube cancer, fallopian tube disorder, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder, primary peritoneal carcinoma | Not yet recruiting | Phase 2 | 2026-10-01 | NCT07843303 | |
| A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line Treatment | SCLC, Extensive Stage | Recruiting | Phase 1 | 2026-02-17 | NCT07413042 | |
| A Phase I Study to Assess the Safety and Efficacy of [225Ac]Ac-DOTATATE in Patients With SSTR+ GEP-Nens | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 1 | 2025-06-26 | NCT06732505 | |
| NW-301 TCR-T in Patients With Advanced Solid Tumor | neoplasm | Not yet recruiting | Phase 1 | 2025-05-04 | NCT06956261 | |
| Phase I Study of OriC902 in Treatment of Advanced HCC | hepatocellular carcinoma | Recruiting | Phase 1 | 2025-03-24 | NCT06891742 |